Previous Article | Next Article 
Infection and Immunity, October 2001, p. 6511-6514, Vol. 69, No. 10
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.10.6511-6514.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Epitope Mapping of Neutralizing Botulinum
Neurotoxin A Antibodies by Phage Display
B. P.
Mullaney,1,2,*
M.
G.
Pallavicini,1,2,3 and
J. D.
Marks2,4
Departments of Laboratory
Medicine,1 Radiation
Oncology,3 and Anesthesia and
Pharmaceutical Chemistry4 and Cancer
Center,2 University of California at San
Francisco, San Francisco, California 94143
Received 15 February 2001/Returned for modification 27 March
2001/Accepted 21 June 2001
 |
ABSTRACT |
Single-chain antibodies neutralize activity and bind nonoverlapping
epitopes of botulinum A neurotoxin. Two phage display epitope libraries
were constructed from the 1.3 kb of binding domain cDNA. The minimal
epitopes selected against the single-chain Fv-Fc antibodies correspond
to conformational epitopes with amino acid residues 1115 to 1223 (S25), 1131 to 1264 (3D12), and 889 to 1294 (C25).
 |
TEXT |
The anaerobic bacterium
Clostridium botulinum produces a potent neurotoxin causing
flaccid paralysis (19). Therapeutic strategies for
toxicity associated with ingestion of contaminated food, infant bowel infection, and infected wounds include active immunization or
passive immunotherapy with neutralizing antibodies. Antibotulinum antibodies exert therapeutic effects by inhibiting cellular receptor binding by the toxin of the heavy chain binding domain (HC)
of botulinum neurotoxin serotype A (BoNT/A) (5, 6, 15, 16, 18,
26). Production of human immunoglobulins from immunized volunteers (2) involves risks of blood-borne contaminants. Thus, monoclonal antibodies (MAbs) with botulinum neurotoxin
neutralizing activity offer an alternative treatment approach.
Recently, we selected antibody (Ab) single-chain variable fragments
(scFv) to BoNT/A from phage libraries constructed using mice immunized
with BoNT/A HC (MAbs S25 and C25) or humans immunized with pentavalent botulinum toxoid (MAb 3D12). scFv bind
nonoverlapping epitopes with Kds of
7.3 × 10
8 M (S25) (1), 1.1 × 10
9 M (C25) (1), and 3.7 × 10
8 M (3D12) (P. Amersdorfer, unpublished data). These
Abs neutralize BoNT/A in a mouse hemidiaphragm assay (170, 50, and 50% longer times to neuroparalysis for C25, S25, and 3D12,
respectively) and are synergistic (1; Amersdorfer,
unpublished). Epitopes of these antibodies have not been mapped,
and the basis for the differential activity is unknown. Gene fragment
libraries provide an attractive approach for epitope mapping
because library members provide direct sequence information about the
epitope (linear and conformational) (7). We used a
gene fragment phage display to map neutralizing antitoxin epitopes.
Epitope libraries.
Two phage libraries were constructed from
1.3 kb of synthetic BoNT/A HC cDNA (GenBank accession no.
U22962) (5). PCR DNA (from phage library BOT1) or plasmid
DNA (from phage library BOT2) was randomly fragmented with DNase
I (10 U/ml) in 10 mM Tris (pH 7.0)-10 mM
MnCl2 for 8 min at 15°C, blunted with T4 polymerase for
30 min at 12°C, and ligated with SfiI restriction
site linkers (link1, 5'-AGCGGCCGCAGGCCATGGAGGCC;
link2, 5'-GGCCTCCATGGCCTGCGGCCGCT). Products of 200 (BOT1) or >300 (BOT2) bp were purified by gel (2%) electrophoresis.
PCR template (100 ng of linker-ligated DNA) was amplified with nested
primer LP5 (5'-GCGGCCGCAGGCCATGGA) for 30 cycles (94°C for
1 min, 55°C for 1 min, 72°C for 1 min). The pORF1 gene
fragment phage display vector was derived from pHEN-1 (10), containing a nonreligatable SfiI insert
cloning site upstream of gene III. Optimized ligation
mixtures were electroporated into Escherichia coli
TG-1. The size distribution of library inserts was evaluated by PCR
with primers flanking the cloning site (Sfiseq5, 5'-TCACCATCATCACGGGGCCAT; Sfiseq3,
5'-GTTTTTGTTCTGCGGCCGTTG) with Pfu polymerase for
30 cycles (94°C for 1 min, 55°C for 1 min, 72°C for 1 min).
DNA sequencing of random clones revealed fragments of HC
vector sequence in both coding orientations. The BOT1 library contains
3 × 107 150- to 300-bp inserts, while the BOT2
library contains 8 × 106 300- to 1,200-bp inserts
(Fig. 1), generously covering the
sequence space (<104 bp).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Size distribution of PCR inserts from unselected BOT1
(A) and BOT2 (B) epitope phage libraries. Individual random clones
were subjected to PCR amplification using primers immediately flanking
the insert cloning site and analyzed on a 1% agarose gel.
|
|
Some unstable scFv unfold when immobilized onto solid surfaces. Thus,
scFv were fused to a human Fc-immunoglobulin G1 scaffold
(
21). Expressed Fc fusion proteins, homodimers with
increased
avidity and stability, retained affinity (confirmed by
BIAcore).
Epitope phage was selected (
17,
24) using
Fc-coated (50-µg/ml)
immunotubes. Random clones from the second round
of selection
were screened by enzyme-linked immunosorbent assay (ELISA)
(
22,
24) on Fc-coated (50-µg/ml) plates, and binding
clones were
detected with a 1:1,000 dilution of horseradish
peroxidase-conjugated
anti-M13. Selected clones did not cross-react
with plastic, albumin,
or immunoglobulin IgG. Positive controls
included anti-erbB2 phage.
The DNA sequences of ELISA-positive clones
with unique insert
sizes were determined, aligned by BLAST
(accession no.
P10845),
and modeled using Rasmol.
Significant enrichment occurred during
selections except
for those from the BOT1 library phage against
MAb C25 mAb (Table
1).
Epitope identification.
DNA sequencing revealed 8, 11, and 2 unique and overlapping clones for MAbs S25, 3D12, and C25, respectively
(Fig. 2). The minimal consensus
epitope regions correspond to holotoxin residues 1115 to 1223 (108 amino acids), 1131 to 1264 (133 amino acids), and 889 to 1294 (405 amino acids) for S25, 3D12, and C25, respectively (Fig. 2). These
relatively large clones suggest complex conformational epitopes
(13). Only the 3D12 antibody bound to the denatured HC fragment, as determined by Western blotting (data not
shown). Fine mapping was performed by "peptide-on-a-pin,"
with 54 peptides (15-mers, overlapping by seven amino acids)
corresponding to the HC sequence (Mimotopes, San Diego,
Calif.). None of the antibodies bound specifically to any of the
peptide pins, confirming conformational epitopes. The BOT1-selected
S25 and 3D12 clones are larger (500 to 600 bp) than those in the
library (150 to 300 bp). In contrast, other gene fragment
selections (50 to 400 bp) from multivalent rather than monovalent
display libraries yield small epitopes (i.e., 50 to 200 bp)
(3, 4, 8, 9, 11, 20, 27) that are perhaps related to
multivalent, smaller fragments with higher functional affinity.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Alignment of epitope phage sequence with botulinum
toxin and binding domain (HC) protein sequences. The DNA
sequence of inserts from ELISA-positive clones was determined and
aligned against the BoNT/A HC sequence using BLAST.
The corresponding residues of each individual clone are indicated at
the N and C termini. The sequences of the S25 and 3D12 clones overlap
the C-terminal binding domain, while the C25 sequence overlaps the
entire binding domain.
|
|
Three-dimensional structure.
Recently, the crystal structure
of BoNT/A (14) revealed that holotoxin is composed of
three distinct functional domains: catalytic (residues 1 to 437),
translocation (residues 448 to 872), and receptor binding
(HC; residues 873 to 1295) (12). A molecular
model overlay of selected epitopes corresponds to the
three-dimensional HC. The BoNT/A binding
domain consists of N- and C-terminal regions (Fig.
3A). The S25 (Fig. 3B) and 3D12 (Fig. 3C)
epitopes map within the C-terminal subdomain, containing the
putative sialo-ganglioside binding site (23, 25).
Based on the botulinum neurotoxin serotype B
structure, BoNT/A sialyllactose corresponds to Trp1265, His1252, and
Glu1202 (Fig. 3). These residues are contained within the 3D12
epitope, proximal to the S25 epitope. Thus, it is likely that
3D12 neutralizes toxin by blocking binding to ganglioside (Fig.
4), while S25 may interfere with binding to this site or to the putative protein receptor (Fig. 4). C25 maps to
a complex epitope that includes the majority of the HC sequence (Fig. 3D), suggesting an epitope of adjacent N- and
C-terminal subdomains (Fig. 4), which would explain why small
epitopes were not identified.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Molecular model overlay of neutralizing epitopes
within the BoNT/A HC binding domain. (A) N-terminal
(yellow) and C-terminal (white) subdomains of BoNT/A HC and
putative ganglioside binding residues Glu1202 (purple), His1252
(green), and Trp1265 (blue). (B) S25 epitope. (C) 3D12 epitope.
(D) C25 epitope. Minimal epitopes identified by phage display
are indicated in red, while the remainder of the binding domain is
indicated in yellow and white. Models were constructed using the
coordinates of BoNT/A by use of Rasmol. S25 and 3D12 recognize the
C-terminal subdomain of the binding domain, while C25 recognizes a
complex epitope comprising the entire binding domain sequence.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 4.
Model of C25, S25, and 3D12 epitopes. A hypothetical
model of the C25, S25, and 3D12 epitopes, based on the
epitopes identified for each Ab by phage display, is shown.
|
|
Epitope mapping provides insight into why a single MAb cannot potently
neutralize a toxin. Broad interaction of the C-terminal
subdomain with
cellular receptors is consistent with the mechanism
of tetanus toxin
(
9). Potent toxin neutralization would require
blockade of
this broad surface, which could not be covered by
a single Ab.
Administration of all three MAbs may more potently
neutralize toxin by
blocking a larger proportion of the binding
surface. Thus, it is
unlikely that smaller peptides or H
C fragments
would be as
potent an immunogen as the complete H
C region would
be.
 |
ACKNOWLEDGMENTS |
We thank David Powers and Agnes Nowakowski for Fc-Ab and Andrew
Bradbury and Peter Pavlik for fine mapping of peptides.
We gratefully acknowledge funding from grant
DAMD-17-98-C-8030/CA78877/K22-85327.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: UCSF Cancer
Center, Box 0808, UCSF, San Francisco, CA 94143-0808. Phone: (415)
476-3657. Fax: (415) 476-8218. E-mail:
mullaney{at}cc.ucsf.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Amersdorfer, P.,
C. Wong,
S. Chen,
T. Smith,
S. Deshpande,
R. Sheridan,
R. Finnern, and J. D. Marks.
1997.
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
Infect. Immun.
65:3743-3752[Abstract].
|
| 2.
|
Arnon, S. S.
1993.
Clinical trial of human botulism immune globulin.
Plenum, New York, N.Y.
|
| 3.
|
Arza, B.,
J. Felez,
R. Lopez-Alemany,
L. A. Miles, and P. Munoz-Canoves.
1997.
Identification of an epitope of alpha-enolase (a candidate plasminogen receptor) by phage display.
Thromb. Haemostasis
78:1097-1103[Medline].
|
| 4.
|
Bluthner, M.,
E. K. Bautz, and F. A. Bautz.
1996.
Mapping of epitopes recognized by PM/Scl autoantibodies with gene-fragment phage display libraries.
J. Immunol. Methods
198:187-198[CrossRef][Medline].
|
| 5.
|
Clayton, M. A.,
J. M. Clayton,
D. R. Brown, and J. L. Middlebrook.
1995.
Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
Infect. Immun.
63:2738-2742[Abstract].
|
| 6.
|
Dertzbaugh, M. T., and M. W. West.
1996.
Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum.
Vaccine
14:1538-1544[CrossRef][Medline].
|
| 7.
|
Fack, F.,
B. Hugle-Dorr,
D. Song,
I. Queitsch,
G. Petersen, and E. K. Bautz.
1997.
Epitope mapping by phage display: random versus gene-fragment libraries.
J. Immunol. Methods
206:43-52[CrossRef][Medline].
|
| 8.
|
Fehrsen, J., and D. H. du Plessis.
1999.
Cross-reactive epitope mimics in a fragmented-genome phage display library derived from the rickettsia, Cowdria ruminantium.
Immunotechnology
4:175-184[CrossRef][Medline].
|
| 9.
|
Fitzsimmons, S. P.,
K. C. Clark,
R. Wilkerson, and M. A. Shapiro.
2000.
Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes.
Vaccine
19:114-121[CrossRef][Medline].
|
| 10.
|
Hoogenboom, H. R.,
A. D. Griffiths,
K. S. Johnson,
D. J. Chiswell,
P. Hudson, and G. Winter.
1991.
Multi-subunit proteins on the surface of filamentous phage: methods for displaying antibody (Fab) heavy and light chains.
Nucleic Acids Res.
19:4133-4137[Abstract/Free Full Text].
|
| 11.
|
Jacobsson, K., and L. Frykberg.
1996.
Phage display shot-gun cloning of ligand-binding domains of prokaryotic receptors approaches 100% correct clones.
BioTechniques
20:1070-1081[Medline].
|
| 12.
|
Krieglstein, K. G.,
B. R. DasGupta, and A. H. Henschen.
1994.
Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains.
J. Protein Chem.
13:49-57[CrossRef][Medline].
|
| 13.
|
Kuwabara, I.,
H. Maruyama,
S. Kamisue,
M. Shima,
A. Yoshioka, and I. N. Maruyama.
1999.
Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients.
J. Immunol. Methods
224:89-99[CrossRef][Medline].
|
| 14.
|
Lacy, D. B.,
W. Tepp,
A. C. Cohen,
B. R. DasGupta, and R. C. Stevens.
1998.
Crystal structure of botulinum neurotoxin type A and implications for toxicity.
Nat. Struct. Biol.
5:898-902[CrossRef][Medline].
|
| 15.
|
LaPenotiere, H. F.,
M. A. Clayton, and J. L. Middlebrook.
1995.
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.
Toxicon
33:1383-1386[Medline].
|
| 16.
|
Lewis, G. E.,
P. S. Angel, and U.S. Army Medical Research Institute of Infectious Diseases.
1981.
Biomedical aspects of botulism.
Academic Press, New York, N.Y.
|
| 17.
|
Marks, J. D.,
H. R. Hoogenboom,
T. P. Bonnert,
J. McCafferty,
A. D. Griffiths, and G. Winter.
1991.
By-passing immunization: human antibodies from V-gene libraries displayed on phage.
J. Mol. Biol.
222:581-597[CrossRef][Medline].
|
| 18.
|
Middlebrook, J. L., and J. E. Brown.
1995.
Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins.
Curr. Top. Microbiol. Immunol.
195:89-122[Medline].
|
| 19.
|
Montecucco, C., and G. Schiavo.
1995.
Structure and function of tetanus and botulinum neurotoxins.
Q. Rev. Biophys.
28:423-472[Medline].
|
| 20.
|
Pereboeva, L. A.,
A. V. Pereboev,
L. F. Wang, and G. E. Morris.
2000.
Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen.
J. Med. Virol.
60:144-151[CrossRef][Medline].
|
| 21.
|
Powers, D. B.,
P. Amersdorfer,
M. A. Poul,
U. B. Nielsen,
M. R. Shalaby,
G. P. Adams, and J. D. Marks.
2001.
Expression of single-chain Fv-Fc fusions in Pichia pastoris.
J. Immunol. Methods
251:123-135[CrossRef][Medline].
|
| 22.
|
Schier, R.,
J. Bye,
G. Apell,
A. McCall,
G. P. Adams,
M. Malmqvist,
L. M. Weiner, and J. D. Marks.
1996.
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
J. Mol. Biol.
255:28-43[CrossRef][Medline].
|
| 23.
|
Shapiro, R. E.,
C. D. Specht,
B. E. Collins,
A. S. Woods,
R. J. Cotter, and R. L. Schnaar.
1997.
Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand.
J. Biol. Chem.
272:30380-30386[Abstract/Free Full Text].
|
| 24.
|
Sheets, M. D.,
P. Amersdorfer,
R. Finnern,
P. Sargent,
E. Lindquist,
R. Schier,
G. Hemingsen,
C. Wong,
J. C. Gerhart,
J. D. Marks, and E. Lindqvist.
1998.
Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.
Proc. Natl. Acad. Sci. USA
95:6157-6162[Abstract/Free Full Text].
|
| 25.
|
Swaminathan, S., and S. Eswaramoorthy.
2000.
Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.
Nat. Struct. Biol.
7:693-699[CrossRef][Medline].
|
| 26.
|
Tacket, C. O.,
W. X. Shandera,
J. M. Mann,
N. T. Hargrett, and P. A. Blake.
1984.
Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.
Am. J. Med.
76:794-798[CrossRef][Medline].
|
| 27.
|
Wang, L. F.,
D. H. Du Plessis,
J. R. White,
A. D. Hyatt, and B. T. Eaton.
1995.
Use of a gene-targeted phage display random epitope library to map an antigenic determinant on the bluetongue virus outer capsid protein VP5.
J. Immunol. Methods
178:1-12[CrossRef][Medline].
|
Infection and Immunity, October 2001, p. 6511-6514, Vol. 69, No. 10
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.10.6511-6514.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hill, K. K., Smith, T. J., Helma, C. H., Ticknor, L. O., Foley, B. T., Svensson, R. T., Brown, J. L., Johnson, E. A., Smith, L. A., Okinaka, R. T., Jackson, P. J., Marks, J. D.
(2007). Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains. J. Bacteriol.
189: 818-832
[Abstract]
[Full Text]
-
Smith, T. J., Lou, J., Geren, I. N., Forsyth, C. M., Tsai, R., LaPorte, S. L., Tepp, W. H., Bradshaw, M., Johnson, E. A., Smith, L. A., Marks, J. D.
(2005). Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization. Infect. Immun.
73: 5450-5457
[Abstract]
[Full Text]
-
Ja, W. W., Olsen, B. N., Roberts, R. W.
(2005). Epitope mapping using mRNA display and a unidirectional nested deletion library. Protein Eng Des Sel
18: 309-319
[Abstract]
[Full Text]
-
Nowakowski, A., Wang, C., Powers, D. B., Amersdorfer, P., Smith, T. J., Montgomery, V. A., Sheridan, R., Blake, R., Smith, L. A., Marks, J. D.
(2002). Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA
99: 11346-11350
[Abstract]
[Full Text]